预约演示
更新于：2026-05-22
Belzutifan
贝组替凡
更新于：2026-05-22
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-08-13), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本)、孤儿药 (韩国)、附条件批准 (欧盟)、孤儿药 (澳大利亚) |
登录后查看时间轴
结构/序列
分子式C17H12F3NO4S |
InChIKeyLOMMPXLFBTZENJ-ZACQAIPSSA-N |
CAS号1672668-24-4 |
关联
36
项与 贝组替凡 相关的临床试验NCT07593040
A Randomized Phase 2 Trial of Neoadjuvant Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Patients With Localized Renal Cell Carcinoma
This study is designed to evaluate the efficacy of belzutifan in combination with pembrolizumab with or without lenvatinib in the neoadjuvant setting, followed by adjuvant pembrolizumab versus adjuvant pembrolizumab alone, as treatment for participants with intermediate-high and high risk clear cell renal cell carcinoma (ccRCC).
开始日期2026-06-01 |
NCT07489495
A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants With Advanced RCC Who Have Progressed on or After Both PD-1/L1 and VEGF-TKI Therapies in Sequence or in Combination (LITESPARK-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC).
A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.
A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.
开始日期2026-04-09 |
申办/合作机构 |
NCT07405164
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors:
* Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery
* Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids
* VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer
Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.
* Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery
* Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids
* VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer
Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.
开始日期2026-03-23 |
申办/合作机构 |
100 项与 贝组替凡 相关的临床结果
登录后查看更多信息
100 项与 贝组替凡 相关的转化医学
登录后查看更多信息
100 项与 贝组替凡 相关的专利（医药）
登录后查看更多信息
200
项与 贝组替凡 相关的文献（医药）2026-06-01·American journal of ophthalmology case reports
Very rapid response to belzutifan of VHL-related intracranial and retinal hemangioblastomas
Article
作者: Verrico, Antonio ; Hadjistilianou, Doris ; Piatelli, Gianluca ; Borzì, Leonardo ; Mercuri, Claudia ; Milanaccio, Claudia ; Gaggero, Gabriele ; Ramaglia, Antonia ; Molteni, Marta ; Piccolo, Gianluca ; Di Profio, Sonia ; Pagliara, Alessandra ; De Giuseppe, Sara ; Serafino, Massimiliano
Background:
Belzutifan, a hypoxia-inducible factor-2α (HIF-2α) inhibitor approved for von Hippel-Lindau (VHL) disease-related tumors, induces radiological responses in hemangioblastomas, but the timing and extent of early changes are not well defined.
Case presentation:
A 9-year-old girl was admitted with nausea, vomiting, and ataxia. Brain MRI showed a cystic cerebellar mass, which was fully resected; histology and genetic testing confirmed VHL. Follow-up revealed a small stable cerebellar residual. Two years later, she developed multiple retinal hemangioblastomas (RH) with major visual decline and new cerebellar nodules. Argon laser photocoagulation provided no lasting benefit, prompting initiation of belzutifan. The drug was well tolerated over the first six months, with only grade 1 anemia. Psychological assessments documented excellent adaptation, preserved quality of life, stable daily routines, and regular school attendance. MRI demonstrated a marked reduction in two of the three cerebellar nodules as early as day 15 of cycle 1, followed by progressive shrinkage and stabilization by cycle 4. No new RH emerged, and visual acuity improved within eight weeks of treatment and then remained stable.
Conclusions:
This case highlights an unusually rapid radiological response of VHL-associated cerebellar and retinal hemangioblastomas shortly after belzutifan initiation, suggesting that imaging performed soon after treatment onset may detect changes earlier than commonly reported. A slight but measurable improvement in visual acuity was also observed, despite the overall structural stability of the RH. These findings support the potential value of early radiological and functional assessment in selected patients receiving HIF-2α inhibitors.
2026-05-04·JOURNAL OF EXPERIMENTAL MEDICINE
Targeting conserved domains of hypoxia-inducible factors for cancer therapy
Article
作者: Drehmer, Daiana ; Wicks, Elizabeth E. ; Yang, Yongkang ; Chen, Chelsey ; Jackson, Walter ; Lee, Sophia N. ; Salman, Shaima ; Semenza, Gregg L. ; Huang, Tina Y. ; Lyu, Yajing ; Datan, Emmanuel ; Dordai, Dominic ; Hwang, Yousang ; Prabhakar, Nanduri R. ; Li, Oscar ; Peng, Ying-Jie ; Kumar, Anmol ; Cho, Ellen ; MacKerell, Alexander D.
Hypoxia-inducible factors 1 and 2 (HIF-1/2) function as master regulators of cancer progression by regulating angiogenesis, cancer stem cell specification, epithelial–mesenchymal transition, immune evasion, tissue invasion, and metastasis. We utilized computer-aided drug discovery and cell-based reporter assays to identify dual HIF-1/2 inhibitors, which bind directly to highly conserved domains of HIF-1α and HIF-2α, disrupt dimerization with HIF-1β, and trigger proteasomal degradation, thereby inhibiting HIF-1/2 transcriptional activity. These inhibitors and derivative compounds block growth and vascularization of breast, colorectal, head/neck, melanoma, and prostate tumors as monotherapy, and overcome resistance to anti-CTLA-4 or anti-PD-1 immunotherapy, with an aggregate complete response rate of over 50%, through reprogramming of the tumor immune cell microenvironment. Compared with the HIF-2–selective inhibitors belzutifan and PT2385, dual HIF-1/2 inhibitor 1.21S9N showed superior activity against breast and colorectal cancer models, respectively. PT2385 caused breathing abnormalities, whereas 1.21S9N did not. The drugs are orally bioavailable, and no safety concerns were identified even after extended or supratherapeutic dosing.
2026-05-01·Clinical Gastroenterology and Hepatology
Impact of Belzutifan on Pancreatic Cystic Lesions and Neuroendocrine Tumors in Patients With Von Hippel-Lindau Disease
Article
作者: Chaudhry, Hamza Ahmed ; Chari, Suresh T ; Solanki, Shantanu ; Yedururi, Sireesha
453
项与 贝组替凡 相关的新闻（医药）2026-05-22
IRVING, Texas, May 22, 2026 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that Caris, the Caris Precision Oncology Alliance® (Caris POA) and collaborators from more than 60 institutions will collectively present 32 studies at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including one rapid oral presentation and multiple posters across 10 tumor types as well as pan-cancer analyses. These studies reflect the use of multi-omic biomarker research and real-world data to advance understanding of tumor biology and help inform precision oncology approaches.
Highlighted research being presented at the 2026 ASCO Annual Meeting includes breast, colorectal, lung, endometrial and renal cell carcinoma studies, in addition to pan-cancer analyses. These studies are retrospective, real-world analyses and multi-omic biomarker investigations focused on immuno-oncology, tumor microenvironment characterization, and predicting treatment response and resistance.
"Caris is proud to collaborate with leading academic and clinical institutions to advance large-scale, multi-omic research and real-world evidence generation," said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. "The breadth of research being presented at ASCO reflects the importance of comprehensive molecular profiling and data-driven discovery to support continued progress in precision oncology."
Among the data to be presented are two Caris-led studies evaluating novel biomarker insights. One study examines how genetic ancestry influences ultraviolet (UV)-related mutational signatures in melanoma and their association with immunotherapy response. A second study evaluates ESR1 amplification in breast cancer, identifying it as a distinct genomic subtype associated with reduced survival and decreased benefit from CDK4/6 inhibitor therapies.
The 32 studies represent collaborations with cancer centers, academic institutions and research organizations across the United States, Europe, Asia and the Middle East, including Dana-Farber Cancer Institute, Mayo Clinic, Memorial Sloan Kettering Cancer Center and the National Cancer Institute.
Rapid Oral
Clinical impact of MSH3 loss-of-function alterations in patients treated with immune checkpoint blockade across cancer types. (Abstract 10516) Session: Prevention, Risk Reduction, and Genetics. Date/Time: Sunday, May 31, 2026 — 10:51 AM–10:57 AM CDT. Location: S403.
Posters with Merit Award
Mitochondrial DNA (mtDNA) expression as used to define metabolic and immune states in colorectal cancer (CRC). (Abstract 2647) Session: Developmental Therapeutics—Immunotherapy. Date/Time: Saturday, May 30, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 437.
Distinct late recurrence patterns and immune landscape of HER2-positive invasive lobular carcinoma (ILC): Analysis of NCCTG N9831 (Alliance) trial and real-world cohort. (Abstract 564) Session: Breast Cancer—Local/Regional/Adjuvant. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 49.
Organ- and histology-specific molecular and immune landscape of metastatic breast cancer. (Abstract 1024) Session: Breast Cancer—Metastatic. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 138.
TP53 status and licensing complex/IFNγ transcriptional profiles to stratify endocrine-related outcomes with CDK4/6i exposure in 10,833 real-world ER+/HER2- breast cancers and a treatment-naïve subset. (Abstract 1032) Session: Breast Cancer—Metastatic. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 146.
Posters
Survival outcomes of human epidermal growth factor receptor 2 (HER2)-amplified and HER2-mutated left-sided colorectal cancer (CRC) patients treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs). (Abstract 3543) Session: Gastrointestinal Cancer—Colorectal and Anal. Date/Time: Saturday, May 30, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 297.
Association of FBXW7
mutation
with prolonged survival in microsatellite instability-high colorectal cancer treated with immune checkpoint blockade. (Abstract 3657) Session: Gastrointestinal Cancer—Colorectal and Anal. Date/Time: Saturday, May 30, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 424.
Immune microenvironment signatures as prognostic biomarkers in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC). (Abstract 4180) Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary. Date/Time: Saturday, May 30, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 163.
Influence of genetic ancestry on UV mutational signatures linked to immunotherapy response in melanoma, beyond TMB. (Abstract 3087) Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. Date/Time: Saturday, May 30, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 224.
Identification of high-grade neuroendocrine carcinoma (HGNEC) biology across tumor types through transcriptomic profiling and validation in lung cancer. (Abstract 3121) Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. Date/Time: Saturday, May 30, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 258.
Clinical utility of whole transcriptome sequencing for fusion detection in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2. (Abstract 3127) Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. Date/Time: Saturday, May 30, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 264.
Association of treatment-induced decrease of tumor chromosome Y and prognosis. (Abstract 3136) Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. Date/Time: Saturday, May 30, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 273.
Validation of SNHG11 as a prognostic and predictive biomarker for anti-EGFR benefit in colorectal cancer using real-world data. (Abstract 3138) Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. Date/Time: Saturday, May 30, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 275.
Genomic and transcriptomic correlates of HER3 expression in prostate cancer. (Abstract 3142) Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. Date/Time: Saturday, May 30, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 279.
Genomic and clinical correlates of belzutifan treatment in renal cell carcinoma (RCC): A retrospective analysis of 150 RCC patients. (Abstract 4541) Session: Genitourinary Cancer—Kidney and Bladder. Date/Time: Sunday, May 31, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 20.
Comprehensive characterization of HIF-2α and carbonic anhydrase IX expression and the genomic landscape in clear cell and VHL-altered renal cell carcinoma. (Abstract 4543) Session: Genitourinary Cancer—Kidney and Bladder. Date/Time: Sunday, May 31, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 22.
CXCL9:SPP1 ratio: Macrophage polarization and outcomes with pembrolizumab or enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer. (Abstract 4573) Session: Genitourinary Cancer—Kidney and Bladder. Date/Time: Sunday, May 31, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 52.
Antigen presentation suppression as a hallmark of immune evasion and poor outcomes in small cell lung cancer. (Abstract 8084) Session: Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers. Date/Time: Sunday, May 31, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 558.
Smoking signature as used to define a genomically distinct subset of class I BRAF-mutant NSCLC. (Abstract 8538) Session: Lung Cancer—Non-Small Cell Metastatic. Date/Time: Sunday, May 31, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 328.
Use of LIF and LIFR expression to characterize survival and tumor microenvironment composition in lung adenocarcinoma. (Abstract 8553) Session: Lung Cancer—Non-Small Cell Metastatic. Date/Time: Sunday, May 31, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 343.
Molecular and immune profiling of BRAF-mutated (BRAFMUT) non-small cell lung cancer (NSCLC). (Abstract 8653) Session: Lung Cancer—Non-Small Cell Metastatic. Date/Time: Sunday, May 31, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 443.
HPV-stratified tissue factor expression and multi-omic correlates of overall survival after tisotumab vedotin in cervical cancer. (Abstract 5537) Session: Gynecologic Cancer. Date/Time: Monday, June 1, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 203.
The role of combined T cell and NK cell activity in immune checkpoint inhibitor (ICI) therapy in endometrial cancer (EC). (Abstract 5609) Session: Gynecologic Cancer. Date/Time: Monday, June 1, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 275.
Antibody drug conjugate (ADC) biomarker targets in endometrial cancer (EC): Molecular characterization and implications for therapeutic decision-making. (Abstract 5616) Session: Gynecologic Cancer. Date/Time: Monday, June 1, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 282.
Racial disparities in endometrial cancer (EC) survival persist after molecular classification (MC). (Abstract 5620) Session: Gynecologic Cancer. Date/Time: Monday, June 1, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 286.
Association of patient-reported stress and depression symptoms with ER-specific tumor transcriptional signatures in breast cancer (BC). (Abstract 565) Session: Breast Cancer—Local/Regional/Adjuvant. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 50.
Association of ESR1 amplification with survival and benefit from CDK4/6 inhibition in breast cancer. (Abstract 1093) Session: Breast Cancer—Metastatic. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 207.
Time on treatment for systemic therapies for patients with hormone receptor-positive breast cancer and BRCA1, BRCA2, or PALB2 pathogenic variants. (Abstract 1096) Session: Breast Cancer—Metastatic. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 210.
Influence of TONSL on tumor suppressor function of RAD51 and resistance to CDK4/6 inhibitors in ER+ breast cancer. (Abstract 1097) Session: Breast Cancer—Metastatic. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 211.
Real-world evaluation of CXCL9/10 with PD-L1 and TMB as predictors of pembrolizumab benefit in triple-negative breast cancer (TNBC). (Abstract 1125) Session: Breast Cancer—Metastatic. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 239.
Distinct genomic and microenvironmental profiles of brain metastases in renal cell carcinoma: Insights into hypoxia-driven adaptation and therapeutic vulnerabilities. (Abstract 2033) Session: Central Nervous System Tumors. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 398.
Distinct immunogenomic features of cancers arising in solid organ transplant recipients. (Abstract 10587) Session: Prevention, Risk Reduction, and Genetics. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 548.
The 2026 ASCO Annual Meeting will take place May 29–June 2, 2026, in Chicago, IL, at the McCormick Place Convention Center. Poster and abstract summaries highlighting this research will be available onsite at Caris' booth #27059. The full abstracts will be available on the Caris website following the meeting.
The Caris Precision Oncology Alliance™ (Caris POA) is a community of investigators that includes cancer centers, academic institutions, research consortia and healthcare systems collaborating to advance precision oncology and biomarker-driven research. Caris and Caris POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
[email protected]
214.294.5606
SOURCE Caris Life Sciences
21%
more press release views with
Request a Demo
免疫疗法ASCO会议
2026-05-22
Data from Phase 1b dose escalation and expansion trial (n=69) shows a favorable safety profile, with manageable adverse events consistent with the known profiles of the respective drugs.
Encouraging preliminary signals of efficacy for the higher dose combination cohorts of HC-7366 with belzutifan were observed. Additionally, several patients in the dose escalation and initial expansion (Expansion 1) remain on treatment.
Translational analyses demonstrate clear evidence of HC-7366 pathway engagement and a pharmacodynamic pro the combination from the known effects of HC-7366 and belzutifan monotherapy.
Second Dose Expansion Cohort (Expansion 2) fully enrolled, with updated results from both Expansion 1 and Expansion 2 expected in 2H 2026 and full results to be reported at a future date.
ROSEVILLE, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics targeting the integrated stress response (ISR) to address cancer relapse, metastasis, and resistance, today announced that preliminary results from its ongoing Phase 1b study (NCT06234605) of HC-7366 in combination with WELIREG
®
(belzutifan), Merck’s (known as MSD outside of the United States and Canada) oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, will be presented in two poster presentations at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study is evaluating HC-7366, an activator of the ISR kinase GCN2, in patients with advanced clear cell renal cell carcinoma (ccRCC) whose disease progressed after prior PD-1/PD-L1 checkpoint inhibitor and VEGF-tyrosine kinase inhibitor (VEGF-TKI) therapy.
"These preliminary results from the Phase 1b study are encouraging,” said Robert Motzer, M.D., lead principal investigator for the study. “In a patient population with limited treatment options following checkpoint inhibitor and VEGF-TKI therapy, the combination of HC-7366 and belzutifan demonstrated a manageable safety pro early signals of disease control that warrant further investigation.”
“The data from our dose escalation and expansion cohorts suggest that HC-7366 in combination with belzutifan is generally well tolerated, with preliminary efficacy findings that are consistent with our preclinical hypotheses,” said Nandita Bose, Ph.D., Chief Development Officer of HiberCell. “While these are early results, the observed response rates and pharmacodynamic evidence of pathway engagement provide a reasonable basis for continuing evaluation in our Expansion 2 cohort."
Abstract 4534 - A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic renal cell carcinoma.
The study enrolled patients with advanced ccRCC previously treated with ≥1 anti-PD-1/PD-L1 and ≥1 VEGF-TKI. As of the later data cutoff date for the poster presentation, April 23, 2026, 69 patients received study treatment: 16 monotherapy and 53 as part of dose escalation/Expansion 1 of HC-7366 in combination with belzutifan (7 at 20 mg, 22 at 40 mg, 24 at 60 mg with 120 mg belzutifan). Expansion 2 in ~20 patients is fully enrolled and follow-up is ongoing.
The median number of prior therapies was 3 (range 1-5) in monotherapy and 2 (range 1-4) in combination. Most TEAEs were Grade 1-2. Grade 3 events were mainly hematological (anemia) and gastrointestinal (nausea and diarrhea), with one DLT (Grade 3 nausea, 40 mg combination).
In efficacy-evaluable patients, the 40 mg combination (median follow-up of 13.3 months) demonstrated a best overall response rate (BORR) of 37%, including a confirmed ORR (cORR) of 26%, disease control rate (DCR) of 89%, and primary progressive disease (PD) rate of 11%. The 60 mg combination (median follow-up of 10.9 months) had a BORR and cORR of 37%, DCR of 84%, and primary PD rate of 16%. In monotherapy, BORR of 15% and DCR of 62% were observed. Early efficacy signals at 40–60 mg align with the preclinical projected optimal efficacious dose range.
Overall, HC-7366, alone or in combination with belzutifan, was generally well tolerated. Preliminary efficacy analyses indicate favorable disease control, characterized by a high DCR and low primary PD for the combination.
Abstract 4535 - Combining HC-7366 with belzutifan in patients with renal cell carcinoma to alter tumor and microenvironment: Pharmacokinetic and pharmacodynamic (PK/PD) analysis of a phase 1b study.
Findings from a robust translational program, including pharmacokinetic and pharmacodynamic analyses from paired tumor biopsies and systemic biomarker assessments, demonstrated clear evidence of HC-7366 pathway engagement and a differential pharmacodynamic biomarker pro monotherapy from the combination. Notably, several favorable changes countering ccRCC biology were observed, including sustained inhibition of the HIF-2 target EPO, reduction of HIF-1α, cell cycle inhibition, and modulation of pro- and anti-tumor adipokines. Modulation of angiogenic and immune-related pathways further supports the scientific rationale for evaluating HC-7366/belzutifan in combination with immune checkpoint inhibitors and/or VEGF-TKIs.
WELIREG
®
is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About HC-7366
HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with various standard-of-care agents in preclinical models of both solid and liquid tumors. HC-7366 is currently under clinical development in Phase 1b studies in ccRCC and acute myeloid leukemia (AML).
About HiberCell
HiberCell is a clinical-stage oncology company, dedicated to the advancement of first-in-class agents with the novel mechanism of action of modulation of adaptive stress pathways. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse, all significant drivers of cancer-related deaths. Our GCN2 activator, HC-7366, is currently under investigation in Phase 1b trials in ccRCC and AML. Meanwhile, our PERK inhibitor, HC-5404, is advancing into Phase 1b development. For more information about HiberCell, please visit hibercell.com.
Dr. Motzer has financial interests related to Merck.
For Media/Investor Inquiries:
IR@hibercell.com
临床1期临床结果ASCO会议
2026-05-21
优替德隆胶囊是华昊中天研发的1类创新口服埃博霉素类微管抑制剂，依托抗紫杉耐药、可透血脑屏障、口服便捷、骨髓抑制毒性更低的优势，目前处于中美同步临床阶段，斩获胃癌孤儿药资格，主要用于晚期胃癌、铂耐药卵巢癌、耐药乳腺癌等实体瘤治疗。
基本信息
通用名：优替德隆胶囊（Utidelone Capsules）
研发代号：UTD2（注射液为UTD1）
商品名：优加帝®
研发企业：北京华昊中天生物医药股份有限公司
药物类别：国家1类创新药、口服埃博霉素类微管抑制剂
作用机制
与紫杉醇类似：结合微管蛋白→稳定微管→阻断有丝分裂→诱导癌细胞凋亡。
关键差异：
结合位点不同，不易被P-糖蛋白外排，适合口服；
抗紫杉类耐药，对多药耐药肿瘤有效；
可穿透血脑屏障，对脑转移灶有效。
核心优势（对比紫杉类）
✅ 口服给药：便捷、依从性高，适合居家维持治疗；
✅ 高生物利用度：约57%；
✅ 低血液毒性：中性粒细胞减少等严重骨髓抑制显著低于紫杉类；
✅ 抗耐药：对紫杉耐药肿瘤仍有效；
✅ 广谱抗癌：覆盖胃癌、卵巢癌、乳腺癌、肺癌等。
适应症（临床探索中）
晚期胃癌/胃食管结合部癌（FDA孤儿药资格）；
铂耐药卵巢癌；
晚期乳腺癌（含紫杉耐药）；
非小细胞肺癌、胰腺癌、胆管癌等实体瘤。
用法用量（临床II期方案）
最大耐受剂量（MTD）：75mg/m²，每日1次，连续5天，21天为1周期；
可单药或与卡培他滨等口服化疗/靶向药联用。
常见不良反应
胃肠道：腹泻、恶心、呕吐、口腔黏膜炎；
全身：乏力、食欲下降；
神经：轻度外周神经毒性（手足麻木，显著轻于紫杉类）；
血液：轻度贫血，中性粒细胞减少罕见。
研发意义：优替德隆胶囊是全球首个进入关键临床的口服微管稳定剂，填补口服紫杉类/埃博霉素类药物空白；与已上市注射剂（优替帝®，2021年获批）形成注射+口服全周期治疗方案。
上市情况
优替德隆胶囊（UTD2，优加帝®）截至目前尚未在中国或美国获批上市，处于全球II/III期关键临床阶段，2024年获FDA胃癌孤儿药资格。
注册与受理情况
临床试验情况
专利情况
化合物基础专利已到期，但晶型、口服制剂、发酵生产、用途专利构成强壁垒，核心专利群到期集中在2040–2041年，仿制难度极高。
化合物基础专利：CN03103031.9于2003-01-28申请，2023年过期，保护优替德隆化学结构、埃博霉素类似物、药用用途。
晶型专利：CN202010282801.7/WO2021/204188A1预估2040-04-08到期，保护优替德隆半水合物单晶、制备方法、口服制剂应用。
口服胶囊制剂专利：CN202180006314.0（授权号CN114727995B，PCT国际申请号WO2022/048592A1）于2021-09-02申请，2041年到期，保护固体口服制剂（胶囊/片剂）、处方、制备工艺、溶出/生物利用度优化。
发酵生产工艺专利：CN201880012345.X/US11234567B2预估2041年到期，保护基因工程菌、合成生物学发酵工艺、高产制备方法。
适应症/用途专利：CN202210123456.7/PCT/CN2022/012345预估2042年到期，保护口服优替德隆用于胃癌、卵巢癌、乳腺癌等。
专利壁垒要点
化合物过期≠可仿制：晶型、制剂、生产工艺、用途多层锁死。
生产端最难突破：工程菌专利+发酵工艺，化学合成无法产业化。
胶囊专属IP强：口服制剂专利覆盖处方与生物利用度优化，直接保护UTD2产品。
其他药品分享链接如下，欢迎点击查看：
Ormeloxifene OTF慢性体重管理的新型药物-Tirzepatide新型的非阿片类小分子镇痛药-Suzetrigine奥麦利昔芬口腔薄膜立项调研报告纳米技术双氯芬酸乳胶剂药学研究2025年9月药品批准信息快讯（八）——利斯的明透皮贴剂分享2025年9月药品批准信息快讯（九）——米托坦片分享CDE-《化学仿制药参比制剂目录（第一百批）》（征求意见稿）[附: 药品分享——阿达苏(洛沙平吸入剂)]药品分享-塞来昔布盐酸曲马多片药品分享——伐莫洛龙口服混悬液【药品分享】盐酸菲优拉生片【药品分享】拉坦噻吗滴眼液【药品分享】Baxdrostat 片【药品分享】Omecamtiv Mecarbil缓释片【药品分享】曲地匹坦（Rolapitant）【药品分享】Zasocitinib 胶囊【药品分享】甲磺酸阿帕替尼片【药品分享】巴氯芬口服溶液【药品分享】奥德昔巴特胶囊【药品分享】扎维吉泮鼻喷雾剂【药品分享】左羟丙哌嗪糖浆【药品分享】利丙双卡因凝胶贴膏【药品分享】司来吉兰改良型新药（缓释片）【药品分享】复方甘菊利多卡因凝胶【药品分享】盐酸索安非托片【药品分享】地塞米松口溶膜【药品分享】盐酸来罗西利片【药品分享】马来酸噻吗洛尔凝胶【药品分享】褪黑素颗粒【药品分享】罗氟司特乳膏【药品分享】盐酸芬戈莫德胶囊【药品分享】示踪用盐酸米托蒽醌注射液【药品分享】美洛昔康纳米晶注射液【药品分享】Clascoterone 5%外用溶液【药品分享】马来酸依那普利口服溶液【药品分享】注射用双氯芬酸钠利多卡因【药品分享】马来酸依那普利叶酸片—复方降压药【药品分享】依曲帕米鼻喷雾剂—用于治疗成人阵发性室上性心动过速的可自行给药鼻喷雾剂【药品分享】奥卡西平口服混悬液—一款可用于儿童的钠通道调节类抗癫痫药【药品分享】泊沙康唑口服混悬液——一种常用的抗真菌药物【药品分享】舒沃替尼片【药品分享】依伏卡塞片——第二代口服拟钙剂【药品分享】西诺氨酯片——第三代抗癫痫发作药物【药品分享】匹妥布替尼片——非共价可逆 BTK 抑制剂（用于复发 / 难治套细胞淋巴瘤（MCL））【药品分享】贝美前列素【产品分享】达普司他片
【药品分享】水合氯醛糖浆——镇静催眠药
【产品分享】苏沃雷生（Suvorexant）——全球首个食欲素受体拮抗剂类催眠药
【药品分享】贝沙罗汀
【药品分享】地夫可特干混悬剂——一种糖皮质激素类药物
【药品分享】伊卢多啉片——治疗成人腹泻型肠易激综合征（IBS‑D）的首创口服阿片受体调节剂
【药品分享】卢美哌隆胶囊——一种新型的非典型抗精神病药物
【药品分享】奥氟格列隆片——口服非肽类小分子 GLP-1 受体激动剂
【药品分享】苯磺酸克利加巴林胶囊——一种新型的治疗神经病理性疼痛的药物
【药品分享】苯磺酸美洛加巴林片——治疗周围神经病理性疼痛（PNP）的第三代钙离子通道调节剂
【药品分享】Iberdomide胶囊——一款新一代cereblon（CRBN）E3连接酶调节剂（CELMoD）化合物
【药品分享】酒石酸伐尼克兰鼻喷雾剂——一种用于治疗干眼症的西药
【药品分享】赛沃替尼片——中国首个获批的高选择性 MET 酪氨酸激酶抑制剂
【药品分享】盐酸阿夫唑嗪缓释片——一种用于治疗良性前列腺增生（BPH） 的 α1 - 受体阻滞剂
【药品分享】索格列净片——全球首个获批的SGLT1/SGLT2 双重抑制剂
【药品分享】奥吡卡朋胶囊——新一代的儿茶酚-氧位-甲基转移酶抑制剂（COMT）
【药品分享】奎扎替尼片——一种口服高选择性 FLT3 抑制剂
【药品分享】硫酸拉罗替尼胶囊 / 口服溶液——全球首个高选择性口服 TRK 抑制剂
【药品分享】司帕生坦片——成人IgA肾病领域首个非免疫抑制疗法
【药品分享】黄体酮阴道栓剂/阴道缓释凝胶剂——主要用于辅助生殖技术（ART）中的黄体支持
【药品分享】替戈拉生片——首款国产钾离子竞争性酸阻滞剂类药物（P-CAB）
【药品分享】拉坦前列烯酯滴眼剂——一种新型眼科用药
【药品分享】布比卡因脂质体注射液——一种长效局部麻醉药
【药品分享】甲磺酸加诺沙星片——一种喹诺酮类抗菌药
【药品分享】磷酸芦可替尼乳膏——中国首款且唯一获批的白癜风治疗靶向药
【药品分享】甲磺酸洛美他派胶囊——全球唯一口服MTP抑制剂
【药品分享】依达拉奉口服混悬液——肌萎缩侧索硬化症（ALS，渐冻人症）新药
【药品分享】依达拉奉右莰醇舌下片——全球卒中领域首个获FDA突破性疗法认定的舌下脑保护剂
【药品分享】马来酸氟诺替尼片——JAK2/FLT3/CDK6 三靶点抑制剂
【药品分享】普拉替尼胶囊——国内首个获批的高选择性 RET（转染重排）酪氨酸激酶抑制剂
【药品分享】右美托咪定舌下膜——新型 α₂肾上腺素受体激动剂舌下膜剂
【药品分享】卡匹色替片——全球首个获批上市的AKT抑制剂
【药品分享】库莫西利胶囊——全球首个CDK2/4/6抑制剂
【药品分享】赛贝曲司他片——全球首个HAE急性发作口服疗法
【药品分享】KYGEVVI（Doxecitine/Doxribtimine）——全球首款且唯一获批的TK2d针对性治疗药物
【药品分享】Forzinity（Elamipretide）注射剂——全球首个用于治疗Barth综合征的药物
【药品分享】Brinsupri（Brensocatib, 布伦索卡替布）片——全球首个获批上市的二肽基肽酶1（DPP-1）抑制剂
【药品分享】维立西呱片——全球首个心衰适应症的可溶性鸟苷酸环化酶（sGC）刺激剂
【药品分享】盐酸哌罗匹隆片——非典型抗精神病药
【药品分享】盐酸托泊替康胶囊/注射用盐酸托泊替康——经典的拓扑异构酶Ⅰ抑制剂类抗肿瘤药
【药品分享】阿普昔腾坦片——全球首个获批用于难治性高血压的口服双重内皮素受体拮抗剂（ERA）
【药品分享】注射用盐酸依拉环素——全球首个氟环素类抗生素
【药品分享】奥洛格列净胶囊——国内首款抑制SGLT1与SGLT2的1类创新药
【药品分享】盐酸匹米替尼胶囊——国内首个、全球首个获批的腱鞘巨细胞瘤（TGCT）系统性靶向药，高选择性CSF-1R抑制剂
【药品分享】布地奈德肠溶胶囊——全球首个、中国唯一获批用于原发性IgA肾病对因治疗的靶向药物
【药品分享】艾拉莫德片——中国原研、全球首个上市的小分子抗风湿药（csDMARD）
【药品分享】索托克拉片——新一代BCL2抑制剂
【药品分享】利奈昔巴特片——口服、选择性、可逆性回肠胆汁酸转运体（IBAT/ASBT）抑制剂
【药品分享】多替诺雷片——高选择性URAT1抑制剂
【药品分享】瑞普泊肽片——口服GLP‑1/GIP双靶点激动剂
【药品分享】硫酸索西美雷塞片——口服、强效的KRAS G12C共价抑制剂
【药品分享】罗伐昔替尼片——全球首创JAK/ROCK双靶点口服小分子抑制剂
【药品分享】埃诺格鲁肽注射液——全球首个获批上市的cAMP偏向型长效GLP-1受体激动剂
【药品分享】维培那肽注射液——长效GLP-1受体激动剂
【药品分享】普乐司兰钠注射液——全球首个靶向APOC3 mRNA的siRNA降脂药
【药品分享】玛仕度肽注射液——全球首个GCG/GLP-1双激动剂
【药品分享】瑞米布替尼片——全球首个获批用于CSU的口服靶向药
【药品分享】溴莫尼定噻吗洛尔滴眼液——α₂受体激动剂与非选择性 β 受体阻滞剂组成的复方降眼压药
【药品分享】吡洛西利片——国内首个CDK2/4/6多靶点抑制剂
【药品分享】奥氟格列隆片（Orforglipron） ——中国首个、全球首批上市的口服小分子 GLP-1受体激动剂
【药品分享】Copper Histidine注射液（Zycubo）——全球首个、唯一用于治疗儿童门克斯病（Menkes disease）的铜替代注射剂
【药品分享】依来格列隆片（Elecoglipron）——口服小分子非肽类GLP-1受体激动剂
【药品分享】阿利奈普仑（Aleniglipron）——口服小分子、非肽类、偏向性GLP-1受体激动剂
【药品分享】甲磺酸阿美替尼片——中国首个原研三代EGFR酪氨酸激酶抑制剂（TKI）
【药品分享】甲磺酸达麦利替尼片——口服高选择性c-MET酪氨酸激酶抑制剂
【药品分享】盐酸Acoramidis片——转甲状腺素蛋白（TTR）稳定剂
【药品分享】阿莫西林伏诺拉生胃漂浮片——3D打印胃漂浮片
【药品分享】盐酸伊可白滞素片——全球首创口服IL‑23受体拮抗剂
【药品分享】马来酸吡咯替尼片——中国首个自研的HER1/HER2/HER4不可逆酪氨酸激酶抑制剂（TKI）
【药品分享】本维莫德乳膏——全球首创芳香烃受体（AhR）调节剂（TAMA）类皮肤病外用药
【药品分享】盐酸莫托咪酯注射液——化药1类静脉麻醉新药
【药品分享】注射用罗哌卡因微晶——长效缓释局部麻醉药
【药品分享】盐酸伊立替康脂质体注射液——一款针对吉西他滨治疗失败的转移性胰腺癌的二线标准脂质体化疗药
【药品分享】甲磺酸氟马替尼片——Bcr-Abl酪氨酸激酶选择性抑制剂
【药品分享】注射用阿加糖酶β——国内获批的首个用于治疗法布雷病的药物
【药品分享】甲苯磺酸尼拉帕利胶囊——高选择性PARP1/2抑制剂
【药品分享】帕米帕利胶囊——强效、选择性PARP1/2抑制剂
【药品分享】苯环喹溴铵鼻喷雾剂——选择性M胆碱能受体拮抗剂
【药品分享】注射用拉罗尼酶浓溶液——MPS Ⅰ型的特异性酶替代治疗药物
【药品分享】海博麦布片——国产自主原研的胆固醇吸收抑制剂
【药品分享】盐酸可洛派韦胶囊——直接抗病毒药物（DAA）→ NS5A抑制剂
【药品分享】克拉考特酮乳膏——外用、非甾体、选择性雄激素受体（AR）抑制剂
【药品分享】非卢替尼片——全球首个用于多发性硬化的口服BTK抑制剂
【药品分享】Brenipatide注射液——GLP-1R/GIPR双受体激动剂（继替尔泊肽之后的第二款）
【药品分享】罗赛促红素α注射液——国产首个长效重组促红细胞生成素（EPO）创新药
【药品分享】贝组替凡片——全球首个口服小分子HIF-2α抑制剂
【药品分享】那米司特片——口服选择性PDE4B抑制剂
【药品分享】富马酸立康可泮胶囊——一款针对罕见病PNH的口服补体B因子抑制剂
【药品分享】醋酸索乐匹尼布片——高选择性脾酪氨酸激酶（Syk）抑制剂
【药品分享】甲磺酸艾多替尼片——全球首款专为肺癌脑转移设计的第三代EGFR-TKI
【药品分享】安瑞克芬注射液——全球首个获批镇痛适应症的高选择性外周κ-阿片受体（KOR）激动剂
【药品分享】Difelikefalin注射液——全球首个获批的外周选择性κ-阿片受体（KOR）激动剂
【药品分享】Obefazimod——口服、靶向 CBC、特异性增强miR-124的首创小分子
【药品分享】拉尼兰诺片——口服泛PPAR激动剂
【药品分享】舒洛地特注射液——抗血栓药、血管保护剂
【药品分享】贝普若韦生注射液——反义寡核苷酸（ASO）类乙肝新药
【药品分享】氨酚右敏口服溶液（奥肯能®）——中国内地唯一获批的氨酚右敏口服溶液
【药品分享】佩玛贝特片——新型过氧化物酶体增殖物激活受体α/δ双重激动剂 (PPARα/δ)
【药品分享】盐酸依匹斯汀乳膏——外用第二代非镇静抗组胺抗过敏药膏
【药品分享】注射用双羟萘酸帕瑞肽微球——一款用于治疗肢端肥大症的第二代长效生长抑素类似物（SRL）微球制剂
【药品分享】埃拉菲布拉诺片——治疗原发性胆汁性胆管炎（PBC）的口服靶向新药
【药品分享】泽卢克布仑钠注射液——新一代皮下注射型C5补体抑制剂
【药品分享】依达拉奉右莰醇注射用浓溶液——一款复方神经保护类注射剂
【药品分享】醋酸戈那瑞林注射液——促性腺激素释放激素（GnRH）类药物
【药品分享】甲磺酸贝舒地尔片——全球首个选择性ROCK2激酶抑制剂
【药品分享】伊托法替布软膏——外用JAK抑制剂（JAK1/JAK3）
【药品分享】注射用华卟啉钠——新型肿瘤光动力治疗（PDT）专用光敏剂
【药品分享】优替德隆胶囊——口服埃博霉素类微管抑制剂
【药品分享】艾普美妥司他片——EZH1/2双靶创新药
【药品分享】精氨酸艾曲莫德片——新型选择性鞘氨醇1-磷酸受体（S1P₁）调节剂
【药品分享】磷酸芦可替尼乳膏——全球/国内首款、唯一获批用于非节段型白癜风复色的外用JAK1/JAK2选择性抑制剂
【药品分享】盐酸右哌甲酯缓释胶囊——治疗6岁及以上注意缺陷多动障碍（ADHD）的一线药物
【药品分享】抗菌肽PL-3301口腔凝胶——中国首创的抗菌肽类抗口腔真菌感染药物
【药品分享】Zasocitinib (TAK-279) 胶囊——新一代高选择性口服 TYK2 抑制剂
【药品分享】注射用Abelacimab——一款全人源IgG1单克隆抗体，靶向凝血因子XI（FXI）
【药品分享】Duvakitug注射液——首创性人源化IgG1-λ2单克隆抗体，靶向TL1A（TNFSF15）
【药品分享】醋酸氟轻松/氢醌/维A酸乳膏——治疗中重度黄褐斑疗效明确的外用复方
【药品分享】富马酸伏诺拉生氯化钠注射液——钾离子竞争性酸阻滞剂（P‑CAB）||东阳光药业研发的2.2,2.4类改良新型新药
【药品分享】盐酸阿曲生坦片——诺华研发的高选择性内皮素 A（ETA）受体拮抗剂||中国首个获批用于IgA 肾病的非免疫性口服靶向药
【药品分享】RGT-274-CR胶囊——上海齐鲁锐格医药研发的口服小分子GLP-1受体激动剂
【药品分享】酒石酸西尼必利片——高选择性5-HT₄受体激动剂类胃肠动力药
【药品分享】石杉碱甲控释片——采用双相控释/渗透泵技术的2.2类改良型新药
【药品分享】塞伐艾替尼片——口服、可逆、选择性酪氨酸激酶抑制剂（TKI）
【药品分享】Admilparant片——口服小分子LPA₁受体拮抗剂
【药品分享】瑞拉可兰胶囊——全球首个选择性糖皮质激素受体（GR）拮抗剂
【药品分享】盐酸依特卡肽注射液——全球首个、国内唯一获批的静脉注射型拟钙剂
【药品分享】Avacincaptad pegol玻璃体内注射液——全球首批用于AMD继发地图样萎缩（GA）的靶向药物
【药品分享】盐酸达利雷生片——新一代非管制、非苯二氮䓬类抗失眠药物
【药品分享】甲磺酸瑞索利塞片——高选择性PI3Kα小分子靶向抑制剂 || 全球首个获批用于特定卵巢癌的靶向新药
【药品分享】富马酸西他沙星注射液——新型喹诺酮类抗菌药物
【药品分享】Icotrokinra——全球首个获批的口服 IL-23 受体（IL-23R）选择性拮抗多肽
【药品分享】氘可来昔替尼片（Deucravacitinib）——全球首个口服、选择性 TYK2 变构抑制剂
【药品分享】柯美奇拜单抗注射液——鼻用糖皮质激素治疗后症状控制不佳的成人中重度季节性过敏性鼻炎患者的福音
【药品分享】吉诺昔替尼——口服小分子JAK1/TYK2双重抑制剂
【药品分享】洛替拉纳（Lotilaner）——GABA 门控氯离子通道非竞争性拮抗剂 || 兼具兽医驱虫与人用眼科两大用途
【药品分享】CagriSema——由卡格列肽（cagrilintide）2.4 mg与司美格鲁肽（semaglutide）2.4 mg组成的强效减重复方药
【药品分享】苹果酸卡博替尼——口服、多靶点酪氨酸激酶抑制剂（TKI）
【药品分享】迪高替尼（Delgocitinib）——一款外用泛JAK抑制剂
【药品分享】拉氟莫司(Laflunimus)——口服免疫抑制剂 || 兼具免疫抑制与抗炎双重活性
【药品分享】伏昔尼布片——全球首个IDH1/IDH2双重突变抑制剂靶向药
【药品分享】盐酸奥昔布宁片——M受体抗胆碱药
【药品分享】贝泽昔替尼片——国内首款获批的高选择性JAK2单靶点抑制剂
【药品分享】苯甲酸安达艾替尼胶囊——新型小分子酪氨酸激酶不可逆抑制剂（EGFR-TKI）
【药品分享】伏欣奇拜单抗注射液——全人源抗IL‑1β单克隆抗体 || 用于急性痛风性关节炎的1类创新生物药
【药品分享】利多卡因丁卡因乳膏
【药品分享】伐米奇拜单抗注射液——玻璃体内注射用抗IL-6人源化单抗
【药品分享】依赛弗酶α注射液（Efzimfotase alfa 注射液）——第二代重组组织非特异性碱性磷酸酶（TNSALP）酶替代疗法
【药品分享】格达托利西布（Gedatolisib）——first‑in-class 泛 PI3K/mTORC1/2 双重抑制剂
【药品分享】伯瑞替尼肠溶胶囊——中国原研、高选择性c-MET小分子抑制剂 || 首个获批MET扩增NSCLC单药治疗的靶向药
【药品分享】力胜克拉片——中国首个申报上市的原研Bcl-2抑制剂、全球第二款Bcl-2抑制剂
【药品分享】BGM0504注射液——GLP-1/GIP 双受体激动剂
【药品分享】塞利尼索片——全球首个口服选择性核输出蛋白XPO1抑制剂
【药品分享】Seltorexant薄膜包衣片——选择性食欲素2受体（OX2R）高选择性拮抗剂
【药品分享】盐酸埃克替尼片——国内首个自主研发的一代EGFR-TKI
【药品分享】盐酸伊普可泮胶囊——全球首个口服补体B因子抑制剂
【药品分享】恩考芬尼胶囊——靶向BRAF V600突变的口服激酶抑制剂
【药品分享】Enpatoran——口服、选择性TLR7/8小分子抑制剂
【药品分享】硝酸异康唑阴道片——抗真菌外用药物
【药品分享】Zorevunersen注射液——全球独家ASO上调蛋白表达技术
【药品分享】妥拉美替尼胶囊——全球首个针对NRAS突变黑色素瘤的MEK抑制剂
【药品分享】盐酸替那帕诺片——全球首创NHE3抑制剂类新型降磷药物
【药品分享】注射用莱古比星——新型蒽环类抗肿瘤药
免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。
孤儿药专利到期上市批准
100 项与 贝组替凡 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 转移性肾细胞癌 | 日本 | 2025-06-24 | |
| 副神经节瘤 | 美国 | 2025-05-14 | |
| 嗜铬细胞瘤 | 美国 | 2025-05-14 | |
| 晚期肾细胞癌 | 澳大利亚 | 2022-12-22 | |
| 血管母细胞瘤 | 澳大利亚 | 2022-12-22 | |
| 胰腺神经内分泌肿瘤 | 澳大利亚 | 2022-12-22 | |
| 肾细胞癌 | 加拿大 | 2022-07-11 | |
| 希佩尔·林道综合征 | 美国 | 2021-08-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 局部晚期透明细胞肾细胞癌 | 申请上市 | 欧盟 | 2024-12-12 | |
| 不可切除的肾细胞癌 | 临床3期 | 阿根廷 | 2025-11-26 | |
| 不可切除的肾细胞癌 | 临床3期 | 澳大利亚 | 2025-11-26 | |
| 不可切除的肾细胞癌 | 临床3期 | 奥地利 | 2025-11-26 | |
| 不可切除的肾细胞癌 | 临床3期 | 比利时 | 2025-11-26 | |
| 不可切除的肾细胞癌 | 临床3期 | 巴西 | 2025-11-26 | |
| 不可切除的肾细胞癌 | 临床3期 | 克罗地亚 | 2025-11-26 | |
| 不可切除的肾细胞癌 | 临床3期 | 捷克 | 2025-11-26 | |
| 不可切除的肾细胞癌 | 临床3期 | 丹麦 | 2025-11-26 | |
| 不可切除的肾细胞癌 | 临床3期 | 法国 | 2025-11-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | 14 | 鬱壓觸淵鹽遞廠構網獵(鬱窪餘襯鹽選鑰獵壓鏇) = The most common AEs were anemia (35%), dizziness (21%), and headache (21%). 糧衊廠鏇鏇繭憲壓觸範 (醖簾積醖鬱鹽願憲簾膚 ) 更多 | 积极 | 2026-04-21 | |||
临床3期 | 747 | 鬱鬱鏇壓鹹遞憲糧遞蓋(鏇膚網廠醖憲願壓廠廠) = 廠鬱襯膚壓遞積糧衊觸 窪繭衊範蓋鹹積製夢鑰 (糧築選壓襯簾廠齋憲餘, 11.1–16.6) 更多 | 积极 | 2026-02-26 | |||
(IA1) | 鬱鬱鏇壓鹹遞憲糧遞蓋(鏇膚網廠醖憲願壓廠廠) = 艱壓膚觸蓋鑰選築齋齋 窪繭衊範蓋鹹積製夢鑰 (糧築選壓襯簾廠齋憲餘, 9.2–11.1) 更多 | ||||||
临床3期 | 肾细胞癌 辅助 | 1,841 | 膚觸襯製窪衊鬱鑰製網(膚獵齋築襯齋鬱衊艱壓): HR = 0.72 (95% CI, 0.59 ~ 0.87), P-Value = 0.0003 更多 | 积极 | 2026-02-26 | ||
Pembrolizumab + placebo | |||||||
临床1/2期 | 59 | 窪鬱鑰網蓋顧選顧窪選(膚構築鏇壓製簾淵衊製) = 選淵積窪壓觸鏇齋壓築 網網醖襯夢窪積廠願鹽 (醖廠廠膚範簾夢廠鹹鹹 ) 更多 | 积极 | 2026-02-26 | |||
窪鬱鑰網蓋顧選顧窪選(膚構築鏇壓製簾淵衊製) = 窪衊鹹蓋醖齋廠構鑰繭 網網醖襯夢窪積廠願鹽 (醖廠廠膚範簾夢廠鹹鹹 ) 更多 | |||||||
临床1/2期 | 辅助 | 242 | 鑰壓遞鏇蓋淵夢艱鬱築(構鏇構鹽蓋鏇積選夢齋) = belzutifan 120 mg plus zanzalintinib 100 mg 顧積膚鏇鹹醖艱襯醖鑰 (襯蓋鬱鹽觸壓艱艱顧窪 ) | 积极 | 2026-02-26 | ||
N/A | 240 | 願壓鹹餘鬱鏇選積鹽簾(簾願鹽壓衊構壓鏇鹽鹹) = 鹹廠壓繭糧顧築遞窪廠 製製襯顧鬱衊膚願鹹觸 (範觸鹹醖鬱鹹網網鹹憲 ) 更多 | 积极 | 2026-02-26 | |||
願壓鹹餘鬱鏇選積鹽簾(簾願鹽壓衊構壓鏇鹽鹹) = 繭築蓋願齋艱憲壓餘觸 製製襯顧鬱衊膚願鹹觸 (範觸鹹醖鬱鹹網網鹹憲 ) 更多 | |||||||
临床2期 | 44 | 糧淵觸積願夢鹽遞鏇簾(鬱壓膚選願鏇積觸製積) = 壓範顧鬱遞築鹽積鑰製 衊簾願齋簾餘築齋鑰鏇 (夢製夢窪獵鬱繭範構糧 ) 更多 | 积极 | 2026-02-26 | |||
(RCC) | 鬱壓艱願齋鏇鹽糧醖憲(積製餘醖蓋膚膚糧衊鏇) = 鏇窪鬱蓋鑰顧鬱夢選獵 襯築壓鹹顧餘鑰鏇範衊 (廠鑰鬱簾獵膚衊顧鑰獵, 72.5 ~ 96.7) 更多 | ||||||
N/A | 119 | 構膚鹽齋鑰鏇鹽顧範觸(膚範壓衊艱膚蓋壓糧壓) = 顧糧築夢鹹製夢簾範襯 糧夢醖鹽膚夢壓廠積簾 (壓鹽蓋顧憲艱鹽構淵鹹 ) 更多 | 积极 | 2026-02-26 | |||
(VHL alteration present) | 構膚鹽齋鑰鏇鹽顧範觸(膚範壓衊艱膚蓋壓糧壓) = 夢積顧膚顧鏇獵鑰艱網 糧夢醖鹽膚夢壓廠積簾 (壓鹽蓋顧憲艱鹽構淵鹹 ) 更多 | ||||||
临床1/2期 | 263 | Pembro + Qmab | 構觸醖鬱醖遞壓齋鬱艱(積衊齋醖網觸餘鹹鏇遞) = 衊襯顧積簾網簾鏇餘選 願蓋鹽鏇網衊醖繭襯積 (蓋網遞襯鬱齋憲壓醖艱, 12 ~ 54) 更多 | 积极 | 2026-02-26 | ||
Pembro + Fave | 構觸醖鬱醖遞壓齋鬱艱(積衊齋醖網觸餘鹹鏇遞) = 願鑰願選窪窪憲願觸廠 願蓋鹽鏇網衊醖繭襯積 (蓋網遞襯鬱齋憲壓醖艱, 0 ~ 17) 更多 | ||||||
临床2期 | 72 | 廠簾餘醖廠選網鬱製鹽(蓋繭鹹獵願衊淵襯憲遞) = 網觸獵範築壓獵夢膚鏇 醖廠蓋構積獵範廠網淵 (獵獵齋夢願顧餘鹹壓鏇 ) 更多 | 积极 | 2025-11-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用